UK Statutory Scheme Rebate Rise Could Cause Product Shortages & Launch Delays

The pharmaceutical industry is calling on the government to take steps to restore the UK as a location for life sciences investment and recognize the role of competition in the branded generics market, but it will need strong evidence to make the most convincing case.

Close-up shot of pills with stamped pound sterling GBP symbol on them.
The statutory scheme is one way to govern drug prices in the UK • Source: Shutterstock

The latest proposed hike in rebates due from companies under the UK’s statutory scheme to control the costs of branded medicines is predicted to add further pressure on medicine supply and could even delay or even stop some product launches in the UK, industry sources have warned. 

The increase in the rebate under the statutory scheme is driven by a need to align with the higher rebate...

More from Europe

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By 

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By 

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.

World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings

 

The European Medicines Agency has started reviewing for potential EU marketing approval six new products, including MaaT Pharma’s microbiota therapeutic for acute-graft-versus-host disease, and AstraZeneca's camizestrant for locally advanced or metastatic breast cancer.

Sponsors Asked, EMA Delivered: One Handbook To Navigate CTIS

 
• By 

The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.

More from Geography

Business Background Of New CDER Director George Tidmarsh

 

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

US FDA Could Seek Stronger Warnings On SSRI Antidepressant Risks During Pregnancy

 
• By 

Testimony during a July 21 ‘expert panel’ could help justify stronger warnings across the class about potential adverse effects on mother and baby. Panelists ranged from clinicians who said depression during pregnancy should be treated, to those who said sadness has been “medicalized."